Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

被引：0

作者：

Vodanovic, Ivana Dora ^{[1
]}

Nekic, Anja Barac ^{[1
]}

Sambula, Lana ^{[2
]}

Tomsic, Karin Zibar ^{[1
]}

Dusek, Tina ^{[1
,3
]}

Kastelan, Darko ^{[1
,3
]}

机构：

[1] Univ Hosp Ctr Zagreb, Dept Endocrinol, Kispaticeva 12, Zagreb 10000, Croatia

[2] Gen Hosp Tomislav Bardek, Dept Nephrol Endocrinol & Diabetol, Koprivnica, Croatia

[3] Univ Zagreb, Sch Med, Zagreb, Croatia

来源：

ENDOCRINE RESEARCH | 2025年 / 50卷 / 01期

关键词：

Adjuvant treatment; adrenal insufficiency; adrenocortical carcinoma; adverse event; hydrocortisone replacement; mitotane; EUROPEAN NETWORK; PLASMA;

D O I：

10.1080/07435800.2024.2402311

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundMitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.MethodsA retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.ResultsMitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.ConclusionCareful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.

引用

页码：50 / 56

页数：7

共 50 条

[31] Mitotane in adrenocortical carcinoma: a profile of its use
Shirley, Matt
DRUGS & THERAPY PERSPECTIVES, 2022, 38 (12) : 508 - 519
[32] Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry
Carmona-Bayonas, Alberto
alvarez-Escola, Cristina
Ballester Navarro, Inmaculada
Hernando Cubero, Jorge
Mangas Cruz, Miguel angel
Garcia-Centeno, Rogelio
Iglesias, Clara
Garcia-Donas, Jesus
Picon, Maria Jose
Paja, Miguel
Gonzalez Batanero, Lorena
Garcia, Lourdes
Alonso Gordoa, Teresa
Lopez, Carlos
Hanzu, Felicia
Martinez-Trufero, Javier
Febrero, Beatriz
Saiz-Lopez, Patricia
Blanco Carrera, Concepcion
Cajal, Teresa Ramon
Veiguela, Brenda
Gressani, Oswaldo
Valdes, Nuria
Jimenez-Fonseca, Paula
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
[33] Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug
Reidy-Lagunes, Diane L.
Lung, Betty
Untch, Brian R.
Raj, Nitya
Hrabovsky, Anastasia
Kelly, Ciara
Gerst, Scott
Katz, Seth
Kampel, Lewis
Chou, Joanne
Gopalan, Anu
Saltz, Leonard B.
ONCOLOGIST, 2017, 22 (09) : 1102 - 1106
[34] Mitotane Effects in a H295R Xenograft Model of Adjuvant Treatment of Adrenocortical Cancer
Lindhe, O.
Skogseid, B.
HORMONE AND METABOLIC RESEARCH, 2010, 42 (10) : 725 - 730
[35] IMPACT OF ADJUVANT MITOTANE ON THE CLINICAL COURSE OF PATIENTS WITH ADRENOCORTICAL CANCER
VASSILOPOULOUSELLIN, R
GUINEE, VF
KLEIN, MJ
TAYLOR, SH
HESS, KR
SCHULTZ, PN
SAMAAN, NA
CANCER, 1993, 71 (10) : 3119 - 3123
[36] Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management
Boulate, Geoffrey
Amazit, Larbi
Naman, Annabelle
Seck, Atmane
Paci, Angelo
Lombes, Anne
Pussard, Eric
Baudin, Eric
Lombes, Marc
Hescot, Segolene
INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 54 (06) : 2149 - 2156
[37] Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience
Masaki Uchihara
Maki Tanioka
Yuki Kojima
Tadaaki Nishikawa
Kazuki Sudo
Tatsunori Shimoi
Emi Noguchi
Akiko Miyagi Maeshima
Kan Yonemori
International Journal of Clinical Oncology, 2021, 26 : 2275 - 2281
[38] Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma
Doghman, Mabrouka
Lalli, Enzo
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2013, 381 (1-2) : 66 - 69
[39] Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics
Zhang, Jie
Wu, Luming
Su, Tingwei
Liu, Haoyu
Jiang, Lei
Jiang, Yiran
Wu, Zhiyuan
Chen, Lu
Li, Haorong
Zheng, Jie
Sun, Yingkai
Peng, Hangya
Han, Rulai
Ning, Guang
Ye, Lei
Wang, Weiqing
FRONTIERS IN ENDOCRINOLOGY, 2024, 15
[40] Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience
Uchihara, Masaki
Tanioka, Maki
Kojima, Yuki
Nishikawa, Tadaaki
Sudo, Kazuki
Shimoi, Tatsunori
Noguchi, Emi
Maeshima, Akiko Miyagi
Yonemori, Kan
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (12) : 2275 - 2281

← 1 2 3 4 5 →